Unmet Needs in IPF- and ILD-Related Pulmonary Hypertension and Emerging Therapy for IPF

Opinion

Video

December 24, 2024

Key Takeaways

Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Personalized treatment approaches are needed to address individual patient variability in IPF and PAH.
Enhanced understanding of pathophysiological mechanisms is crucial for novel therapeutic target development.

Steven Nathan, MD, discusses additional noteworthy data from CHEST 2024 on emerging therapies for IPF and PAH and highlights his excitement for ongoing research focused on improving early detection, personalized treatments, and improving long-term patient outcomes.

Please discuss any other data in IPF or PAH released at CHEST 2024 that you find noteworthy to share with colleagues.
Outside of CHEST 2024, what ongoing research efforts are you most excited about in the treatment and management of IPF and PAH, and what are some key areas where you think further research is needed to continue improving patient outcomes?

Source link

Steven D. Nathan, MD

Key Takeaways

Must Read

Leave a Comment Cancel Reply